Document Detail

Ancillary benefits of prenatal maternal serum screening achieved in the California program.
MedLine Citation:
PMID:  20730796     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the extent of fetal structural abnormalities, other than neural tube and abdominal wall defects (AWDs), identified by California's Prenatal Screening Program.
METHODS: The Quad Marker Prenatal Screening records of 516,172 women were examined for screening interpretation and the diagnosis of structural abnormalities detected via follow-up. Women who were screen-positive for trisomy 21, trisomy 18, neural tube defects (NTDs) or Smith-Lemli-Opitz syndrome (SLOS) received follow-up services at state-approved Prenatal Diagnosis Centers (PDCs). Detailed reports of services and diagnostic information were linked in a database to the original screening results.
RESULTS: A total of 26 323 women received follow-up ultrasound services at the PDCs in the study time period. Of these women, 1085 (4.1%) were identified as having fetuses with significant structural abnormalities, other than NTDs (n = 207) or AWDs (n = 254). In addition to the structural abnormalities, 225 cases of fetal demise, 4 molar pregnancies, 15 cases of twin-to-twin transfusion, and 92 cases with placental abnormalities were identified.
CONCLUSION: While Prenatal Screening Programs do not explicitly screen for structural abnormalities other than NTDs and AWDs, clearly many other structural abnormalities may be associated with a screen-positive status. Thus, the detection of these additional structural defects can be considered an ancillary program benefit.
N Neely Kazerouni; Robert J Currier; Christina Hodgkinson; Sara Goldman; Fred Lorey; Marie Roberson
Related Documents :
23410596 - Regulation of progesterone signaling during pregnancy: implications for the use of prog...
23438156 - Metabolic syndrome in normal and complicated pregnancies.
11928766 - Triploid pregnancy detected incidentally by down's syndrome screening.
19481846 - How do prospective parents who decline prenatal screening account for their decision? a...
18313456 - Determinants of adverse perinatal outcome in high-risk women with abnormal uterine arte...
12785716 - Relaxin: a pregnancy hormone as central player of body fluid and circulation homeostasis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Prenatal diagnosis     Volume:  30     ISSN:  1097-0223     ISO Abbreviation:  Prenat. Diagn.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-29     Completed Date:  2011-01-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8106540     Medline TA:  Prenat Diagn     Country:  England    
Other Details:
Languages:  eng     Pagination:  981-7     Citation Subset:  IM    
Copyright Information:
© 2010 John Wiley & Sons, Ltd.
Genetic Disease Screening Program, California Department of Public Health, 850 Marina Bay Parkway, Richmond, CA 94804, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
California / epidemiology
Congenital Abnormalities / diagnosis*,  epidemiology,  prevention & control
Mass Screening / methods*
Pregnancy / blood*
Pregnancy Trimester, First
Prenatal Diagnosis*
Voluntary Programs
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The burden of emergency department use for sickle-cell disease: an analysis of the national emergenc...
Next Document:  Live cell imaging and systems biology.